Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. decreased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 34.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,750 shares of the medical equipment provider’s stock after selling 1,939 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Intuitive Surgical were worth $1,265,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Portside Wealth Group LLC lifted its stake in shares of Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after acquiring an additional 3,054 shares in the last quarter. Kades & Cheifetz LLC purchased a new position in Intuitive Surgical during the 4th quarter valued at about $230,000. Blair William & Co. IL increased its holdings in Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after acquiring an additional 11,400 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Intuitive Surgical by 21.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after acquiring an additional 129,194 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ISRG. Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Raymond James raised their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Wells Fargo & Company raised their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a report on Friday, January 19th. Barclays lifted their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Finally, Mizuho lifted their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $375.70.

Intuitive Surgical Stock Up 0.3 %

Shares of ISRG stock opened at $378.55 on Wednesday. The stock has a market cap of $134.18 billion, a price-to-earnings ratio of 75.26, a price-to-earnings-growth ratio of 5.86 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm’s 50 day moving average price is $387.90 and its two-hundred day moving average price is $342.17.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The firm had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same period in the previous year, the company posted $0.91 earnings per share. Intuitive Surgical’s revenue was up 16.6% compared to the same quarter last year. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Over the last three months, insiders have sold 248,418 shares of company stock valued at $95,927,097. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.